Overview

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Status:
Not yet recruiting

Trial end date:
2025-03-10

Target enrollment:

Participant gender:

Summary

To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19-CD22 CAR+ T cells.

Phase:

Phase 1

Details

Lead Sponsor:

Hrain Biotechnology Co., Ltd.

Collaborator:

Ruijin Hospital